Search Results
Your search for A matches 32603 pages
Showing 251 - 300Novel Biomarkers May Improve Diagnosis of Gallbladder Cancer
Plasma proteins may be capable of distinguishing gallbladder cancer from cholecystitis, which could reduce unnecessary procedures and improve treatment options in patients with suspected gallbladder cancer, according to a recent study published by Nouairia et al in JHEP Reports. Gallbladder cancer...
Consumer Survey Reveals Common Misconceptions About HPV and HPV-Related Cancer
A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma
In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...
Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC
In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...
Overcoming Resistance to KRAS G12C Inhibitors in Pancreatic and Colorectal Cancers
A study evaluating the genetic landscape of candidate primary resistance alterations relevant to KRAS targeting in KRAS G12C–mutant colorectal cancers and pancreatic ductal adenocarcinomas (PDAC) has found that putative resistance alterations are prevalent in these cancers. The finding may explain...
MSTFCRC Updates Recommendations for Colonoscopy Preparation
Updated consensus recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing the quality of bowel preparation for colonoscopy. The document, published today by Jacobson et al, presents clinical strategies to improve bowel preparation as they apply...
Postradiotherapy Survival in Patients With Glioblastoma Multiforme and Low-Grade Gliomas
Investigators may have uncovered how radiotherapy affects survival in patients with glioblastoma multiforme and low-grade glioma, according to a recent study published by Veviorskiy et al in Aging. The findings highlighted key biological differences between these cancer types. Background...
Is There a Link Between Tattoos and Increased Cancer Risk?
Skin cancers and lymphoma may be more prevalent among individuals with tattoos compared with those without tattoos, according to a recent study published by Clemmensen et al in BMC Public Health. Prior research has shown that tattoo ink does not just remain at the site of injection—instead, when...
Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC
Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...
Clinical Characteristics of Breast Cancer in Young BRCA Carriers
In a study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, and colleagues identified clinical characteristics of breast cancer in young women carrying germline pathogenic variants in BRCA1 vs BRCA2 and examined the effect of prediagnostic BRCA testing on outcomes. Study...
Francis S. Collins, MD, PhD, Retires From the National Institutes of Health
Francis S. Collins, MD, PhD, announced in a statement his retirement as Director of the National Institutes of Health (NIH), effective February 28, 2025. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years—Barack...
Novel Prediction Score May Estimate Risk of Early-Onset Colorectal Cancer, Precancerous Polyps
Researchers have developed and validated a novel prediction model that may be capable of estimating the risk of colorectal cancer and advanced precancerous polyps in patients younger than 45 years, according to a recent study published by Wehbe et al in Digestive Diseases and Sciences. Background...
Chemotherapy, Endocrine Therapy May Have Different Long-Term Physical Health Effects in Breast Cancer Survivors
The receipt of chemotherapy or endocrine therapy without chemotherapy could be associated with different long-lasting physical health declines among breast cancer survivors compared with those without breast cancer, according to a recent study published in JAMA Network Open. Background Physical...
Idecabtagene Vicleucel vs Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Hansen et al found that standard-of-care ciltacabtagene autoleucel was associated with better efficacy outcomes and increased risk of some toxicities vs standard-of-care idecabtagene vicleucel in patients with relapsed or...
Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...
Palbociclib Plus Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative Metastatic Breast Cancer
In an overall survival analysis of a South Korean phase II trial (Young-PEARL) reported in The Lancet Oncology, Ahn et al found no benefit with palbociclib plus exemestane and leuprorelin vs capecitabine in premenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast...
The Importance of Diversity in Clinical Research
The Cancer Drug Development Forum (CDDF) held its annual conference in the Netherlands from February 3–5, 2025. Under the title “Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials,” the workshop focused on diversity and real-world evidence in anticancer...
Combination of MCL-1 and SRC Inhibitors May Increase Cell Death in AML
An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...
Decoding Varying Risk of Colorectal Cancer Among Different Steatotic Liver Disease Subgroups
Investigators have found that the risk of colorectal cancer may vary among steatotic liver disease subgroups and could be higher in patients with alcoholic liver disease, according to a recent study published by Kimura et al in Clinical Gastroenterology and Hepatology. Background Lifestyle-related...
Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
It’s a fast-paced world, no two ways about it. People move on from one event to another. We have to move on either for our own sake or the sake of someone near and dear. In the medical field, patients come and go, surgeries are performed, treatments are given, and everybody moves on. Being kind to...
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases. Study Details In the open-label multicenter study, 63...
Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer
Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Long-term data from the phase...
Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction
Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...
Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk
Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option. Background Gastric cancer is the fourth...
ASTRO Issues Clinical Guideline on Radiation Therapy for Anal Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in...
Overall Survival and HRQOL with Addition of [177Lu]Lu-PSMA-617 to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...
Top Picks From SABCS 2024
Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...
Cabozantinib/Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
In a multicohort phase Ib study (COSMIC-021) reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues identified the activity of cabozantinib plus atezolizumab in a cohort of patients with locally advanced or metastatic urothelial carcinoma according to first-line...
Participation in Early Trials May Provide Some Patients With Access to Cancer Drugs Later FDA Approved
Nearly 20% of patients participating in middle-stage cancer drug trials may receive treatments that eventually receive U.S. Food and Drug Administration (FDA) approval, according to a recent study published by Ouimet et al in the Journal of the National Cancer Institute. The findings may have...
BRCA1 Gene Mutations May Not Be Key to Prostate Cancer
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
Novel Antibody-Toxin Conjugate Evaluated in Early Study
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combined the benefits of antibody-drug...
New Study Uncovers Low Uptake of Supportive Care at End of Life in Patients With Advanced Cancer
Investigators have found that nearly 50% of patients with advanced cancer may receive potentially aggressive treatment at the expense of supportive care, despite considerable efforts to improve the quality of end-of-life care in the United States, according to a recent study published by Kwon et al ...
Physical Activity May Help Colorectal Cancer Survivors Live as Long as Those in General Population
Physical activity may help colorectal cancer survivors achieve long-term survival rates comparable to those of individuals in the general population, according to a recent study published by Brown et al in Cancer. Background Patients with colorectal cancer often face higher rates of premature...
Evaluation of Surrogate Endpoints for Overall Survival in Neoadjuvant Randomized Trials in Early Breast Cancer
In a study reported in Journal of Clinical Oncology, Conforti et al found that invasive disease–free survival with sufficient follow-up may be the best surrogate for overall survival in neoadjuvant randomized trials in early breast cancer. Study Details The study involved 11 trials with 15...
Immunotherapy for Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
In a single-center retrospective study reported in JAMA Oncology, Lochrin et al identified activity of ipilimumab/nivolumab in melanoma brain metastases after progression on anti–PD-1 treatment. Study Details The study involved 28 patients with prior PD-1 inhibitor treatment who developed...
ASCO Engages in Judicial and Legislative Advocacy to Protect NIH Funding
ASCO issued the following statement on February 21, 2025: "Cancer research is the core of ASCO’s mission and cancer cannot be conquered without continued robust federal investment for biomedical research through the National Institutes of Health (NIH) and the National Cancer Institute (NCI)....
Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC
Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer...
Masumi Ueda Oshima, MD, on, a Posttransplant GVHD Prophylaxis Strategy
Masumi Ueda Oshima, MD, of Fred Hutchinson Cancer Center, discusses findings from a phase II trial exploring the use of cyclosporine and sirolimus combined with mycophenolate mofetil or posttransplant cyclophosphamide as graft-vs-host disease (GVHD) prophylaxis.
Cancer Mortality Rates Among Black Patients vs Other Racial, Ethnic Groups
Although the cancer mortality rate among Black patients in the United States has dropped over the past 30 years, this patient population may continue to experience a disproportionately elevated cancer burden compared with other patient populations, according to a recent study published by Saka et...
The Death of Alexei Navalny and the Discovery of Cancer Chemotherapy
Remembering Alexi Anatolyevich Navalny: The Russian opposition leader, lawyer, anticorruption activist, and political prisoner, Alexi Navalny died in the Arctic Wolf prison in Siberia approximately 1 year ago on February 16, 2024. He was designated a Prisoner of Conscience by Amnesty...
Ageism and Its Role in the Treatment of Cancer
Age discrimination, often referred to as ageism, is an increasingly pressing issue within society. Although it can impact individuals across all age groups, older adults are particularly vulnerable. According to the U.S. Census Bureau projections, by 2040, individuals aged 65 and older will...
Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer
Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...
Effect of High-Risk Cytogenetic Abnormalities in Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Kaiser et al found that the presence of two or more high-risk cytogenetic abnormalities was associated with poorer outcomes in patients with newly diagnosed multiple myeloma (MM) and relapsed or refractory MM. Study Details The...
Darolutamide in Triple-Negative, AR-Positive Advanced Breast Cancer
In a French phase II trial (UCBG 3-06 START) reported in The Lancet Oncology, Bonnefoi et al found that treatment with the antiandrogen darolutamide did not reach the clinical benefit endpoint in patients with triple-negative, androgen receptor (AR)-positive advanced breast cancer. Triple-negative...
Cryotherapy With Taxane Infusion: Strategy for Preventing Peripheral Neuropathy in Breast Cancer
In a meta-analysis reported in the journal Breast Cancer Research and Treatment, Kumar et al found that the use of cryotherapy decreased the incidence of moderate or worse peripheral neuropathy by more than 50% in patients with breast cancer who received paclitaxel or nab-paclitaxel. Cryotherapy...
Case 3: Relapsed/Refractory Nodal Marginal Zone Lymphoma
This is Part 3 of Evolving Treatment Landscape of Indolent Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Laurie Sehn, Gilles Salles, and Sonali Smith discuss the treatment of relapsed/refractory nodal marginal zone...
Case 2: Third-Line Treatment of Relapsed/Refractory Follicular Lymphoma
This is Part 2 of Evolving Treatment Landscape of Indolent Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Laurie Sehn, Gilles Salles, and Sonali Smith discuss the third-line treatment of relapsed/refractory...
Case 1: Second-Line Treatment of Early Relapsing Follicular Lymphoma
This is Part 1 of Evolving Treatment Landscape of Indolent Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Laurie Sehn, Gilles Salles, and Sonali Smith discuss the second-line treatment of early relapsing follicular...
Betty Hamilton, MD: Research Highlights in GVHD
Betty Hamilton, MD, of Cleveland Clinic, outlines key data from a clinical session she co-chaired on graft-vs-host disease (GVHD), including the role of JAK inhibitors in the prevention of the condition and novel therapies for the management of acute GVHD.
William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer
William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).
